

THURSDAY, MAY 7TH 2026

ANU - Museum of the Jewish People, Tel Aviv

08:00-09:00 *Registration, Gathering, & Exhibition*

09:00-09:30 *Opening Remarks & Greetings*

Acute Myeloid Leukemia (AML)

Chairpersons: **Ofir Wolach, MD** | **Yakir Moshe, MD**

Session 1

09:30-11:10

09:30-09:50 | Managing Differentiation Syndrome in 2026: Steps Beyond Steroids
Dr. Eytan M. Stein, MD, Memorial Sloan Kettering Cancer Center, NY, USA

09:50-10:05 | Triplet Strategies for AML
Courtney DiNardo, MD, University of Texas MD Anderson Cancer Center, Houston, TX, USA

10:05-10:25 | Secondary AML
Stéphane de Botton, MD, Institut Gustave Roussy, Villejuif (IGR), France

10:25-10:40 | TBC
Gail Roboz, MD, Weill Cornell Medicine, The New York Presbyterian Hospital, NY, USA

10:40-11:00 | 2026 AML Induction Therapy: What Does it Mean?
Richard Stone, MD, Dana Farber Cancer Institute, Boston, MA, USA

11:00-11:10 | AML Panel Discussion

11:10-11:30 *Coffee Break & Exhibition*

Acute Lymphoblastic Leukemia (ALL)

Chairpersons: **Irina Amitai, MD** | **Tsila Zuckerman, MD**

Session 2

11:30-12:35

11:30-11:45 | Research and Progress in B-Cell ALL at MD Anderson 2026
Hagop Kantarjian, MD, University of Texas MD Anderson Cancer Center, Houston, TX, USA

11:45-12:00 | Frontline Treatment for Ph+ ALL in 2026
Nicholas J Short, MD, University of Texas MD Anderson Cancer Center, Houston, TX, USA

12:00-12:15 | A Chemo-Free Approach Should be the New Standard for Adult Ph+ ALL.
Evidence from the First Phase 3 Study

Robin Foà, MD, Department of Translational and Precision Medicine, Sapienza, University of Rome, Italy

Chronic Lymphocytic Leukemia (CLL)

Chairpersons: **Liron Hofstetter, MD** | **Yair Herishanu, MD**

Session 3

12:25–13:30

12:25–12:45 | Diagnosis and New Treatment Options in Richter Transformation
Dr. Barbara Eichhost, MD, University Hospital Cologne, Germany

12:45–13:00 | Frontline Treatment of Chronic Lymphocytic Leukemia in 2026
Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, USA

13:00–13:20 | Refractory CLL in 2026: Diagnostic and Therapeutic Approaches
Jan A. Burger, MD, University of Texas MD Anderson Cancer Center, Houston, TX, USA

13:20–13:30 | CLL Panel Discussion

13:30–14:20 *Lunch & Exhibition*

Myeloproliferative Neoplasms (MPN)

Chairpersons: **Adi Shacham–Abulafia, MD** | **Moshe Yeshurun, MD**

Session 4

14:20–15:05

14:20–14:35 | Myeloproliferative Neoplasms Latest Updates
Lucia Masarova, MD, University of Texas MD Anderson Cancer Center, Houston, TX, USA

14:35–14:55 | Myelofibrosis and Cytopenia : Prognosis and Treatment
Mauricette Michallet, MD, Centre Léon Bérard, Lyon, France

14:55–15:05 | MPD Panel Discussion

Cellular Therapy

Chairpersons: **Avichai Shimoni, MD** | **Moshe Gatt, MD**

Session 5

15:05–15:40

15:05–15:20 | Beyond RIC and MAC, is there a Better Conditioning Regimen for AML?
Koen van Besien, MD, PhD, UH Seidman Cancer Center, Cleveland, OH, USA

15:20–15:35 | Bispecific CARs Targeting CD19 and CD20 for Relapsed, Refractory DLBCL
Nirav N. Shah, MD, Medical College of Wisconsin, Milwaukee, WI, USA

15:35–15:40 | Cellular Therapy Panel Discussion

15:40–15:50 *Closing Remarks*

FRIDAY, MAY 8TH 2026

Port Tower Hotel, Tel Aviv

08:00-08:40 *Gathering*

Chronic Myeloid Leukemia (CML)

Chairpersons: Pia Raanani, MD | Merav Leiba, MD

Session 6

08:40-10:15

08:40-09:00 | Should Additional Genetic Abnormalities Drive 1st Line Treatment Choices?

Delphine Rea, MD, Hopital Saint-Louis, Paris, France

09:00-09:20 | Mutations in CML: the Good, the Bad, the Ugly

Simona Soverini, PhD, Alma Mater Studiorum Universita di Bologna, Italy

09:20-09:40 | Present Routine Clinical Management of CML Patients in Italy and how it Will Probably Change in 2026

Giuseppe Saglio, MD, University of Turin, Italy

09:40-10:00 | Optimizing Quality of Life in CML and CMPN

Philipp Le Coutre, MD, Charité – Universitätsmedizin Berlin, Germany

10:00-10:15 | CML Panel Discussion

10:15-10:35 *Coffee Break*

Lymphomas and Plasma Cell Dyscrasias

Chairpersons: Juliana Vaxman, MD | Ronit Gurion, MD

Session 7

10:35-11:50

10:35-10:50 | Next Steps for Hodgkin Lymphoma

Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, NY, USA

10:50-11:10 | Amyloidosis: when Dara Fails What's Next?

Morie Gertz, MD, Mayo Clinic Rochester, MN, USA

11:10-11:25 | TBC

Steve Horwitz, MD, Memorial Sloan Kettering Cancer Center, NY, USA

11:25-11:40 | Relapse FL: CAR-T or Bispecific Antibody

Gilles Salles, MD, Memorial Sloan Kettering Cancer Center, NY, USA

11:40-11:50 | Lymphomas and Plasma Cell Dyscrasias Panel Discussion

MDS & Bone Marrow Failure Syndromes

Chairpersons: Renana Robinson, MD | Anat Gafter-Gvili, MD

Session 8

11:50-12:50

11:50-12:05 | CMML Updates 2025 and Beyond

Eric Padron, MD, Moffitt Cancer Center, Tampa, FL, USA

12:05-12:20 | New Paradigms in MDS

Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, USA

12:20-12:35 | How Do We Change the Standard of Care for Higher Risk Myelodysplastic Syndromes

David A Sallman, MD, Moffitt Cancer Center, Tampa, FL, USA

12:35-12:50 | Aplastic Anemia Management in 2026

Régis Peffault De La Tour, MD, PhD, Saint-Louis Hospital, Paris, France

12:50-13:00 | MDS & Bone Marrow Failure Syndromes Panel Discussion

13:00-13:05 *Closing Remarks*